US Patent

US10385078 — Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-YL) piperidin-1-YL]phenyl}pyrimidine-2,4-diamine

Method of Use · Assigned to Ariad Pharmaceuticals Inc · Expires 2035-11-10 · 9y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent discloses crystalline forms of brigatinib, also known as Alunbrig, and methods of their preparation and use.

USPTO Abstract

Crystalline forms of brigatinib, pharmaceutical compositions comprising the same, and methods of their preparation and use of the same are disclosed herein.

Drugs covered by this patent

Alunbrig (brigatinib) · Takeda

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2837`	—	Alunbrig
`U-2837`	—	Alunbrig
`U-2837`	—	Alunbrig

Patent Metadata

Patent number: US10385078
Jurisdiction: US
Classification: Method of Use
Expires: 2035-11-10
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Ariad Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.